i actually stephen mylan has been dubbed the most controversial publicly traded a health care company by some analysts. most significant his specialty. was because of concern even among legislators here in the u.s. before generic competition and speaking of generic. drug buying groups has led to falling prices for manufacturers such as milan that's why they called penny has been trying to develop more complex generics and copies of biotech drugs jose luis de haro with a look into a big health care story there thank you jose. alternative meat products company beyond meat saw its 2nd quarter revenue break passed estimates to more than $67000000.00 now that's $15000000.00 more than analysts had anticipated and beyond meat said it expects that trend to continue amid strong demand for the company's plant based burgers and sausages is forecasting a revenue gain of a whopping 170 percent on its full year revenue to $240000000.00 fee. you know that little facebook like button in the corner of so many websites well it's but at the center of a very big court case in europe for several years now